Thu, 25 Apr 2013 | DIVISION SALE
It has been confirmed that Lucozade and Ribena are on the market, with analysts predicting the sale of the well loved brands could bring in up to £1 billion.
There has already been plenty of interest in the brands and Sir Andrew Witty, chief executive of parent company GlaxoSmithKline (GSK) said the firm hopes a large drinks company will buy the brands.
In a statement he said: “[We] concluded that the tremendous growth potential of these iconic brands, particularly outside the ‘core’ western markets, could be better leveraged by companies with existing category presence and infrastructure in these regions.”
The pharmaceuticals group will proceed with the sell off if it can attract a high enough price for the brands.
Beecham owned Lucozade and Ribena before its merger with SmithKline in 2000. Lucozade, previously known as Glucozade, was created by Thomas Beecham in 1927, after searching for ways to give sick people a form of energy easy to intake.
Dr Vernon Charley invented Ribena in 1938, on the back of looking to use pure fruit juices for milkshakes. Its name Ribena comes from the Latin word for blackcurrant: ribes nigrum. The drink was given as a source of vitamin C in hospitals, schools and care homes following a government decree during the Second World War.
For the first three months of 2013 worldwide sales of Ribena rose by 2 per cent, while Lucozade sales fell by 2 per cent and by 7 per cent in Europe. GSK recorded that revenues had dropped by 2 per cent to £6.4 billion for the quarter.
____________________________________________________________________________
Related news:
Lucozade and Ribena prepped for a sell off
Britvic and AG Barr argue merger 'would not harm consumers'
This unique and renowned freehold bar and restaurant in the heart of York City Centre offers over 250 covers across its spacious interior, pavement seating, and a rare rooftop terrace.
FREEHOLD
A well established and strongly profitable engineering business, located in the Midlands. The company will be an attractive acquisition for both a larger trade buyer and also those looking for a stable engineering business.
This European pharmacy manufacturer specialises in providing custom clinical trial batches for leading pharmacy companies across the continent, playing a crucial role in their R&D efforts.
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.